ArticleJournal of ovarian research2026
Clinical value of clinical symptoms, serum biomarkers, and coagulation parameters for ovarian endometrioma diagnosis.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian endometriotic cysts represent a prevalent form of endometriosis and are typically identifiable via imaging modalities. Nonetheless, differentiating endometriotic cysts from other benign non-endometriotic ovarian cysts, such as mature teratomas or serous and mucinous cystadenomas, can occasionally pose significant diagnostic challenges. This study aimed to develop a simplified diagnostic model integrating clinical symptoms, tumor markers, inflammatory indices, and coagulation parameters to distinguish endometriosis from other benign ovarian cysts.
methodsA retrospective analysis was conducted on 424 histopathologically confirmed ovarian endometrioma patients and 351 with non-endometriotic benign ovarian cysts (January 2024–March 2025). Clinical data (age, dysmenorrhea, cyst size), serum tumor markers (CA125, CA19-9, HE4), inflammatory indicators (WBC, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio ), and coagulation parameters (PT, APTT, TT) were collected. Independent predictors were identified via multivariable logistic regression, and diagnostic performance was assessed using ROC analysis.
resultsDysmenorrhea prevalence (68.16% vs. 40.46%, P < 0.001) and cyst size (7.00 cm vs. 6.10 cm, P < 0.001) were significantly higher in the EMs group. CA125 and HE4 levels, inflammatory markers (WBC, NLR, PLR), and coagulation times (PT, APTT) were elevated in endometriosis (P < 0.001). Multivariate analysis identified dysmenorrhea (OR = 1.977, 95% CI:1.227–3.186, P = 0.005), CA125 (OR = 1.067, 95% CI: 1.052–1.081, P < 0.001), HE4 (OR = 0.988, 95% CI: 0.981–0.995, P < 0.001), and PT (OR = 3.234, 95% CI:2.212–4.728, P < 0.001) as independent factors. A combined model (dysmenorrhea + CA125 + HE4 + PT) achieved superior diagnostic accuracy (AUC = 0.925, 95% CI:0.904–0.945) versus CA125 alone (AUC = 0.895).
conclusionThe non-invasive diagnostic model combining dysmenorrhea, CA125, HE4, and PT effectively distinguishes ovarian endometrioma from other benign ovarian masses. It serves as a practical, complementary tool to imaging, potentially enhancing preoperative decision-making and reducing unnecessary surgical interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.